Oxford University’s coronavirus vaccine stops 70% of people developing COVID symptoms

Following Pfizer and Moderna’s COVID-19 vaccine triumph, proving ninety-five per cent protection, a large-scale trial has shown that the University of Oxford’s coronavirus vaccine stops seventy per cent of people developing COVID symptoms.

Despite this, Oxford’s vaccine is easier to store, significantly cheaper and easier to distribute compared to the other two; thus, it will play a significant role in tackling the pandemic – if approved by regulators.

If the dose is perfected, data suggests that it could increase protection up to ninety per cent. The UK government has already pre-ordered one-hundred million doses of Oxford’s vaccine, which is enough to immunise fifty million people.

Oxford University conducted the study in more than twenty thousand volunteers, half from Brazil and the other half from the UK. Within the study, there were one hundred and one cases of COVID in people who received a dummy injection and thirty cases of COVID in people who had two doses of the vaccine. The researches discovered that it works out at seventy per cent protection.